Breaking the Glycemic–Distress Loop & Building Metabolic Memory
STAR RTM, a CME on diabetes distress and early glycaemic control
Friday, 18 September 2026 Marigold Hotel, Begumpet, Hyderabad A round table meeting hosted by Beta Cell Academy
Revision notes from this CME, written from the speaker's own slides. The talk ran in three parts, ending with a live demonstration of the PAID-5 tool.
Part 1
The Glycaemic-Distress Loop and Its Screening
Dr Khizer Hussain Junaidy, MD (Pharmacology), Diabetologist & Bariatric Physician
Poor glycaemic control and diabetes distress feed each other, so distress should be asked about and measured with a validated tool at routine visits.
Poor glycaemic control is common in Indian practice (Borgharkar et al., BMJ Open Diabetes Research and Care 2019). It also fuels diabetes distress, and distress in turn worsens control, forming a vicious cycle (Sendekie et al., Front Med 2025).
The EASD 2025 evidence-based clinical guideline asks us to recognise diabetes distress as a core element of care in both type 1 and type 2 diabetes. It aims to standardise assessment and management, and gives Good Practice Statements for assessment along with GRADE-based recommendations for management.
EASD 2025 Good Practice Statements A.1 to A.8 set out the assessment steps: discuss the emotional side of diabetes at every consultation, ask open-ended questions about the burden of living with diabetes, use a valid and reliable tool, and reassess at regular intervals as part of the annual cycle of care.
The same statements also cover what follows the score. Acknowledge and discuss the person's assessment whatever the finding, record it in the clinical notes, share it with the relevant team members, and make a joint plan with the person when distress is identified.
ADA 2026 Standards of Care state that diabetes distress should be routinely screened and managed as part of standard diabetes care, not treated as an optional add-on.
In the ADA 2026 table of psychosocial concerns in adults with type 2 diabetes, diabetes distress carries strong evidence (+++) for higher HbA1c, more macrovascular and microvascular complications, poorer self-care behaviours, comorbid psychosocial concerns, lower quality of life and higher mortality.
Two validated tools were reviewed. The PAID scale has 20 items; item scores are summed and multiplied by 1.25 to give a total out of 100, where 40 and above indicates severe diabetes distress and any single item scored 3 or 4 indicates moderate to severe distress. The Diabetes Distress Scale, developed ten years later, is a 17-item tool with four subscales: emotional burden, regimen, interpersonal and physician distress.
In clinicAsk one open-ended question about the emotional burden of diabetes at every consultation, then use a validated tool at regular intervals and record the finding in the notes.
Part 2
Metabolic Memory and the Legacy Effect
Dr Khizer Hussain Junaidy, MD (Pharmacology), Diabetologist & Bariatric Physician
Early tight glycaemic control leaves a lasting legacy effect, while delay in intensification raises cardiovascular risk, so acting early helps both present well-being and future outcomes.
In patients with type 2 diabetes and poor glycaemic control, a one-year delay in treatment intensification was associated with significantly increased risks of myocardial infarction, heart failure, stroke and composite cardiovascular events (Paul et al., Cardiovasc Diabetol 2015).
The glucocentric route to lower cardiovascular risk in type 2 diabetes has three parts: prolonged reduction in ambient hyperglycaemia, reduction in short-term and long-term glycaemic variability, and reduction in hypoglycaemia.
Early tight HbA1c control yields long-term benefit, and this is what is meant by the legacy effect or metabolic memory (Laiteerapong et al., Diabetes & Aging Study, Diabetes Care 2019).
The concept came from the DCCT trial. Its follow-up EDIC study showed that patients given early intensive glycaemic control had a lower risk of complications over time than those on conventional treatment, even after later glucose control became similar. UKPDS and Steno-2 then confirmed the long-term advantage of early intensive control.
Metabolic memory cuts both ways. Hyperglycaemia can drive continued progression of complications even after control improves, because lack of intensive management early on leads to prolonged, largely irreversible inflammatory and oxidative changes in tissues such as the kidney and retina (Dong et al., Sig Transduct Target Ther 2024).
The two goals align: early tight glycaemic control builds metabolic memory for long-term protection and at the same time lowers diabetes distress, improving quality of life and present well-being.
Initial combination therapy was discussed as one way to reach control early (Sethi et al., Cureus 2025; Kim et al., Endocrinol Metab 2024). In GLIMSI, a real-world multicentre Indian study of 1,235 patients with type 2 diabetes who were treatment-naive or uncontrolled on dual therapy with HbA1c about 7-9%, a sitagliptin plus glimepiride plus metformin fixed-dose combination over 12 weeks reduced HbA1c by about 1.13% (8.2% to 7.06%, p<0.0001), with FBG down about 42 mg/dL, PPG down about 55-65 mg/dL, 17% reaching HbA1c below 6.5% and weight down about 2.5 kg (Zaveri et al., PLoS One 2026).
In clinicIntensify treatment early rather than waiting, because a one-year delay in an uncontrolled patient raises cardiovascular risk and forfeits the long-term protection of metabolic memory.
Part 3
PAID-5 Tool Demonstration
Dr Khizer Hussain Junaidy, MD (Pharmacology), Diabetologist & Bariatric Physician
The five-item PAID-5 takes one to two minutes, scores 0 to 20, and a score of 8 or above signals elevated distress needing action.
PAID-5 asks which of five diabetes issues are currently a problem: feeling scared when thinking about living with diabetes, feeling depressed when thinking about living with diabetes, worrying about the future and the possibility of serious complications, feeling that diabetes takes up too much mental and physical energy, and coping with complications of diabetes.
Each item is rated from 0 to 4: not a problem (0), minor problem (1), moderate problem (2), somewhat serious problem (3), serious problem (4). The five item scores are summed, giving a total from 0 to 20. Administration takes about 1-2 minutes.
A score below 8 indicates low distress. Standard diabetes management and routine clinical follow-up are recommended.
A score of 8 or above indicates elevated distress. This warrants exploratory dialogue, identifying the drivers of distress, lifestyle coaching, or referral for psychological support.
The session also presented an ADA 2026 aligned triage workflow for what to do at a score of 8 or above, along with the 7 As model (Diabetes UK, 2019c) and a downloadable patient guide.
In clinicAdminister PAID-5 in one to two minutes at follow-up, and at a score of 8 or above open an exploratory conversation about what is driving the distress.